Astellas to accelerate ocular disease therapies via $5.9b acquisition

A $5.9 billion acquisition of biotech Iveric Bio by Astellas is set to accelerate development of treatments for blinding retinal diseases.

Related Keywords

Pravinu Dugel ,Prashant Khadayate ,Astellas Pharma ,Naoki Okamura ,Iveric Bio ,Berry Merger Sub Inc ,Drug Administration ,Astellas Us Holding Inc ,Globaldata Pharma Intelligence Center ,Iveric Bio Inc ,Pharma Analyst ,Avacincaptad Pegol ,Age Related Macular Degeneration ,Pharma Intelligence ,Berry Merger Sub ,